ES2394799T3 - Métodos para predecir y superar la resistencia a quimioterapia en cáncer de ovario - Google Patents
Métodos para predecir y superar la resistencia a quimioterapia en cáncer de ovario Download PDFInfo
- Publication number
- ES2394799T3 ES2394799T3 ES04815833T ES04815833T ES2394799T3 ES 2394799 T3 ES2394799 T3 ES 2394799T3 ES 04815833 T ES04815833 T ES 04815833T ES 04815833 T ES04815833 T ES 04815833T ES 2394799 T3 ES2394799 T3 ES 2394799T3
- Authority
- ES
- Spain
- Prior art keywords
- gene
- expression
- sirna
- cisplatin
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010033128 Ovarian cancer Diseases 0.000 title claims abstract description 113
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 111
- 238000000034 method Methods 0.000 title claims description 63
- 238000002512 chemotherapy Methods 0.000 title claims description 44
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 377
- 210000004027 cell Anatomy 0.000 claims abstract description 315
- 108020004459 Small interfering RNA Proteins 0.000 claims abstract description 130
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 59
- 108010015695 S100 calcium binding protein A10 Proteins 0.000 claims abstract description 54
- 102100029796 Protein S100-A10 Human genes 0.000 claims abstract description 51
- 239000003112 inhibitor Substances 0.000 claims abstract description 50
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 39
- 229940044683 chemotherapy drug Drugs 0.000 claims abstract description 31
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 191
- 229960004316 cisplatin Drugs 0.000 claims description 191
- 230000014509 gene expression Effects 0.000 claims description 190
- 206010028980 Neoplasm Diseases 0.000 claims description 123
- 108020004999 messenger RNA Proteins 0.000 claims description 122
- 239000012472 biological sample Substances 0.000 claims description 62
- 102000004169 proteins and genes Human genes 0.000 claims description 61
- 230000000694 effects Effects 0.000 claims description 54
- 238000011282 treatment Methods 0.000 claims description 52
- 201000011510 cancer Diseases 0.000 claims description 46
- 101000653788 Homo sapiens Protein S100-A11 Proteins 0.000 claims description 44
- 102100029811 Protein S100-A11 Human genes 0.000 claims description 44
- 102000003900 Calpain-2 Human genes 0.000 claims description 43
- 108090000232 Calpain-2 Proteins 0.000 claims description 43
- 150000001875 compounds Chemical class 0.000 claims description 37
- 238000012360 testing method Methods 0.000 claims description 35
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 claims description 32
- 238000004458 analytical method Methods 0.000 claims description 30
- 108090000192 Methionyl aminopeptidases Proteins 0.000 claims description 29
- 229940127089 cytotoxic agent Drugs 0.000 claims description 28
- 239000000523 sample Substances 0.000 claims description 27
- 230000002829 reductive effect Effects 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 19
- 230000035945 sensitivity Effects 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- 230000012010 growth Effects 0.000 claims description 16
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 14
- 238000002474 experimental method Methods 0.000 claims description 13
- 230000007423 decrease Effects 0.000 claims description 12
- 210000001072 colon Anatomy 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 11
- 238000011529 RT qPCR Methods 0.000 claims description 10
- 108020004635 Complementary DNA Proteins 0.000 claims description 9
- 239000013068 control sample Substances 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 8
- 230000002611 ovarian Effects 0.000 claims description 8
- 229910052697 platinum Inorganic materials 0.000 claims description 7
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 claims description 6
- 239000005090 green fluorescent protein Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- 206010059866 Drug resistance Diseases 0.000 claims description 4
- 230000030279 gene silencing Effects 0.000 claims description 4
- 238000010200 validation analysis Methods 0.000 claims description 4
- 108010032088 Calpain Proteins 0.000 claims description 3
- 102000007590 Calpain Human genes 0.000 claims description 3
- 238000003753 real-time PCR Methods 0.000 claims description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 2
- 230000010473 stable expression Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000030070 Malignant epithelial tumor of ovary Diseases 0.000 claims 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 230000001965 increasing effect Effects 0.000 description 176
- 108020004414 DNA Proteins 0.000 description 149
- 241000282414 Homo sapiens Species 0.000 description 114
- 239000004055 small Interfering RNA Substances 0.000 description 109
- 239000000047 product Substances 0.000 description 73
- 238000000636 Northern blotting Methods 0.000 description 62
- 235000018102 proteins Nutrition 0.000 description 58
- 238000003752 polymerase chain reaction Methods 0.000 description 51
- 150000007523 nucleic acids Chemical class 0.000 description 43
- 230000002441 reversible effect Effects 0.000 description 35
- 102000039446 nucleic acids Human genes 0.000 description 34
- 108020004707 nucleic acids Proteins 0.000 description 34
- 230000003247 decreasing effect Effects 0.000 description 32
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 29
- 102100034866 Kallikrein-6 Human genes 0.000 description 29
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 27
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 27
- 102100023479 Vinexin Human genes 0.000 description 27
- 101710187710 Vinexin Proteins 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 27
- 150000001413 amino acids Chemical class 0.000 description 27
- 230000009467 reduction Effects 0.000 description 27
- 102100037118 Scavenger receptor class B member 1 Human genes 0.000 description 26
- 102100039725 AH receptor-interacting protein Human genes 0.000 description 25
- 101000959526 Homo sapiens AH receptor-interacting protein Proteins 0.000 description 25
- 101000605522 Homo sapiens Kallikrein-1 Proteins 0.000 description 25
- 102100025418 Zinc finger MYM-type protein 4 Human genes 0.000 description 25
- 102100027674 CTD small phosphatase-like protein Human genes 0.000 description 24
- 101000725950 Homo sapiens CTD small phosphatase-like protein Proteins 0.000 description 24
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 24
- 101000669667 Homo sapiens RNA-binding protein with serine-rich domain 1 Proteins 0.000 description 24
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 24
- 102100039323 RNA-binding protein with serine-rich domain 1 Human genes 0.000 description 24
- 108091005487 SCARB1 Proteins 0.000 description 24
- 102000016589 Calponin-2 Human genes 0.000 description 23
- 108050006169 Calponin-2 Proteins 0.000 description 23
- 102100038712 Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1 Human genes 0.000 description 23
- 101000883304 Homo sapiens Cap-specific mRNA (nucleoside-2'-O-)-methyltransferase 1 Proteins 0.000 description 23
- 101000788741 Homo sapiens Zinc finger MYM-type protein 4 Proteins 0.000 description 22
- 102100029228 Insulin-like growth factor-binding protein 7 Human genes 0.000 description 22
- 101150018665 MAPK3 gene Proteins 0.000 description 22
- 102100022083 Grancalcin Human genes 0.000 description 21
- 101710124985 Grancalcin Proteins 0.000 description 21
- 102100023609 Nucleoside diphosphate kinase, mitochondrial Human genes 0.000 description 21
- 201000010099 disease Diseases 0.000 description 21
- 102100036498 Dual specificity testis-specific protein kinase 2 Human genes 0.000 description 20
- 102100029531 Fas-activated serine/threonine kinase Human genes 0.000 description 20
- 102100034049 Heat shock factor protein 2 Human genes 0.000 description 20
- 101000865408 Homo sapiens Double-stranded RNA-specific adenosine deaminase Proteins 0.000 description 20
- 101000714156 Homo sapiens Dual specificity testis-specific protein kinase 2 Proteins 0.000 description 20
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 20
- 102100037001 Next to BRCA1 gene 1 protein Human genes 0.000 description 20
- 238000000376 autoradiography Methods 0.000 description 20
- 229940079593 drug Drugs 0.000 description 20
- -1 fused fingers Proteins 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- 102100039776 39S ribosomal protein L4, mitochondrial Human genes 0.000 description 19
- 102100029791 Double-stranded RNA-specific adenosine deaminase Human genes 0.000 description 19
- 101710117201 Fas-activated serine/threonine kinase Proteins 0.000 description 19
- 101000667416 Homo sapiens 39S ribosomal protein L4, mitochondrial Proteins 0.000 description 19
- 101000782180 Homo sapiens WD repeat-containing protein 1 Proteins 0.000 description 19
- 102100036551 WD repeat-containing protein 1 Human genes 0.000 description 19
- 108010008598 insulin-like growth factor binding protein-related protein 1 Proteins 0.000 description 19
- 206010009944 Colon cancer Diseases 0.000 description 18
- 101100404397 Homo sapiens NME4 gene Proteins 0.000 description 18
- 210000001519 tissue Anatomy 0.000 description 18
- 101001016883 Homo sapiens Heat shock factor protein 2 Proteins 0.000 description 17
- 208000029742 colonic neoplasm Diseases 0.000 description 17
- 239000002299 complementary DNA Substances 0.000 description 17
- 230000000973 chemotherapeutic effect Effects 0.000 description 16
- 230000001086 cytosolic effect Effects 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 13
- 101150088682 HMT-1 gene Proteins 0.000 description 12
- 101100490834 Homo sapiens ALG1 gene Proteins 0.000 description 12
- 101100216116 Homo sapiens PRMT2 gene Proteins 0.000 description 12
- 102100031782 Metallothionein-1L Human genes 0.000 description 12
- 101710196487 Metallothionein-1L Proteins 0.000 description 12
- 230000027455 binding Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 102100022988 Protein arginine N-methyltransferase 2 Human genes 0.000 description 11
- 230000002759 chromosomal effect Effects 0.000 description 11
- 108091026890 Coding region Proteins 0.000 description 10
- 101001130686 Homo sapiens Ras-related protein Rab-22A Proteins 0.000 description 10
- 102100031516 Ras-related protein Rab-22A Human genes 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 10
- 239000013604 expression vector Substances 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 9
- 108700026244 Open Reading Frames Proteins 0.000 description 9
- 101000582254 Homo sapiens Nuclear receptor corepressor 2 Proteins 0.000 description 8
- 238000000134 MTT assay Methods 0.000 description 8
- 231100000002 MTT assay Toxicity 0.000 description 8
- 108010064462 N-acetylleucyl-leucyl-norleucine Proteins 0.000 description 8
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 210000000349 chromosome Anatomy 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 239000002853 nucleic acid probe Substances 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- TYIRBZOAKBEYEJ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxopurin-7-yl)ethyl 2-[1-methyl-5-(4-methylbenzoyl)pyrrol-2-yl]acetate Chemical compound C1=CC(C)=CC=C1C(=O)C(N1C)=CC=C1CC(=O)OCCN1C(C(=O)N(C)C(=O)N2C)=C2N=C1 TYIRBZOAKBEYEJ-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000011269 treatment regimen Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 description 5
- 101000788678 Homo sapiens Zinc finger MYM-type protein 1 Proteins 0.000 description 5
- 101000788669 Homo sapiens Zinc finger MYM-type protein 2 Proteins 0.000 description 5
- 101000788739 Homo sapiens Zinc finger MYM-type protein 3 Proteins 0.000 description 5
- 101000788744 Homo sapiens Zinc finger MYM-type protein 5 Proteins 0.000 description 5
- 101000788738 Homo sapiens Zinc finger MYM-type protein 6 Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- MSHZHSPISPJWHW-UHFFFAOYSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)NC(=O)CCl)CCC21CO2 MSHZHSPISPJWHW-UHFFFAOYSA-N 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical group C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 description 5
- 229960000936 fumagillin Drugs 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 230000008521 reorganization Effects 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 230000005026 transcription initiation Effects 0.000 description 5
- 230000005030 transcription termination Effects 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 101100210350 Candida albicans (strain SC5314 / ATCC MYA-2876) WOR1 gene Proteins 0.000 description 4
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 4
- 108010077077 Osteonectin Proteins 0.000 description 4
- 102000009890 Osteonectin Human genes 0.000 description 4
- 102100022985 Protein arginine N-methyltransferase 1 Human genes 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 108010085279 eukaryotic translation initiation factor 5A Proteins 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000004481 post-translational protein modification Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 238000013519 translation Methods 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 101000909256 Caldicellulosiruptor bescii (strain ATCC BAA-1888 / DSM 6725 / Z-1320) DNA polymerase I Proteins 0.000 description 3
- 102100032537 Calpain-2 catalytic subunit Human genes 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 101710177611 DNA polymerase II large subunit Proteins 0.000 description 3
- 101710184669 DNA polymerase II small subunit Proteins 0.000 description 3
- 102000008014 Eukaryotic Initiation Factor-2 Human genes 0.000 description 3
- 108010089791 Eukaryotic Initiation Factor-2 Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 101000867692 Homo sapiens Calpain-2 catalytic subunit Proteins 0.000 description 3
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 3
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 3
- 101001112313 Homo sapiens Nucleoside diphosphate kinase, mitochondrial Proteins 0.000 description 3
- 101000836075 Homo sapiens Serpin B9 Proteins 0.000 description 3
- 101000661807 Homo sapiens Suppressor of tumorigenicity 14 protein Proteins 0.000 description 3
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 3
- 101710181812 Methionine aminopeptidase Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 101000902592 Pyrococcus furiosus (strain ATCC 43587 / DSM 3638 / JCM 8422 / Vc1) DNA polymerase Proteins 0.000 description 3
- 108091030071 RNAI Proteins 0.000 description 3
- 101150077199 S100a10 gene Proteins 0.000 description 3
- 102100037942 Suppressor of tumorigenicity 14 protein Human genes 0.000 description 3
- 101710161999 Zinc finger MYM-type protein 4 Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 235000006109 methionine Nutrition 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- WCKQPPQRFNHPRJ-UHFFFAOYSA-N 4-[[4-(dimethylamino)phenyl]diazenyl]benzoic acid Chemical compound C1=CC(N(C)C)=CC=C1N=NC1=CC=C(C(O)=O)C=C1 WCKQPPQRFNHPRJ-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 229940088872 Apoptosis inhibitor Drugs 0.000 description 2
- 101150072950 BRCA1 gene Proteins 0.000 description 2
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000206602 Eukaryota Species 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101000740659 Homo sapiens Scavenger receptor class B member 1 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 241001365914 Taira Species 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 239000000158 apoptosis inhibitor Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000011500 cytoreductive surgery Methods 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000009274 differential gene expression Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 108091006086 inhibitor proteins Proteins 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000002742 methionines Chemical group 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 210000003632 microfilament Anatomy 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000009223 neuronal apoptosis Effects 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000011518 platinum-based chemotherapy Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 238000011272 standard treatment Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- ALMQDMPRSWZSDO-ULQDDVLXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-acetamido-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]hexanoic acid Chemical group CCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O ALMQDMPRSWZSDO-ULQDDVLXSA-N 0.000 description 1
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 108020004463 18S ribosomal RNA Proteins 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- 102100026926 60S ribosomal protein L4 Human genes 0.000 description 1
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 description 1
- 101710159080 Aconitate hydratase A Proteins 0.000 description 1
- 101710159078 Aconitate hydratase B Proteins 0.000 description 1
- 108010038798 Actin Depolymerizing Factors Proteins 0.000 description 1
- 102000015693 Actin Depolymerizing Factors Human genes 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 1
- 102100026792 Aryl hydrocarbon receptor Human genes 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 108700040618 BRCA1 Genes Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940121926 Calpain inhibitor Drugs 0.000 description 1
- 102100035037 Calpastatin Human genes 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 102000003668 Destrin Human genes 0.000 description 1
- 108090000082 Destrin Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101710146518 Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 1
- 108030004420 Fas-activated serine/threonine kinases Proteins 0.000 description 1
- 102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
- 108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
- 108090001064 Gelsolin Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 108010061414 Hepatocyte Nuclear Factor 1-beta Proteins 0.000 description 1
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 1
- 101000691203 Homo sapiens 60S ribosomal protein L4 Proteins 0.000 description 1
- 101000840577 Homo sapiens Insulin-like growth factor-binding protein 7 Proteins 0.000 description 1
- 101000577080 Homo sapiens Mitochondrial-processing peptidase subunit alpha Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 101000757216 Homo sapiens Protein arginine N-methyltransferase 1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000590687 Homo sapiens U3 small nucleolar ribonucleoprotein protein MPP10 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 230000027311 M phase Effects 0.000 description 1
- 101150024075 Mapk1 gene Proteins 0.000 description 1
- 206010027457 Metastases to liver Diseases 0.000 description 1
- 102100028379 Methionine aminopeptidase 1 Human genes 0.000 description 1
- 101710161855 Methionine aminopeptidase 1 Proteins 0.000 description 1
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 101000873929 Mus musculus Squamous cell carcinoma antigen recognized by T-cells 3 Proteins 0.000 description 1
- RJWLAIMXRBDUMH-ULQDDVLXSA-N N-Acetylleucyl-leucyl-methioninal Chemical compound CSCC[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(C)=O RJWLAIMXRBDUMH-ULQDDVLXSA-N 0.000 description 1
- 101710167853 N-methyltransferase Proteins 0.000 description 1
- 101150115413 NBR1 gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 1
- 102000013901 Nucleoside diphosphate kinase Human genes 0.000 description 1
- MSHZHSPISPJWHW-PVDLLORBSA-N O-(chloroacetylcarbamoyl)fumagillol Chemical compound C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)NC(=O)CCl)C[C@@]21CO2 MSHZHSPISPJWHW-PVDLLORBSA-N 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010089430 Phosphoproteins Proteins 0.000 description 1
- 102000007982 Phosphoproteins Human genes 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 101710204571 Protein phosphatase PP2A regulatory subunit A Proteins 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 102000044126 RNA-Binding Proteins Human genes 0.000 description 1
- 101710105008 RNA-binding protein Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108050002651 Retinoblastoma-like protein 2 Proteins 0.000 description 1
- 101150022426 S100a11 gene Proteins 0.000 description 1
- 101150036757 SPARC gene Proteins 0.000 description 1
- 101100457453 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) MNL1 gene Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102000039471 Small Nuclear RNA Human genes 0.000 description 1
- 102100026834 Sorbin and SH3 domain-containing protein 1 Human genes 0.000 description 1
- 102100026901 Sorbin and SH3 domain-containing protein 2 Human genes 0.000 description 1
- 101710089386 Sorbin and SH3 domain-containing protein 2 Proteins 0.000 description 1
- GFKPPJZEOXIRFX-UHFFFAOYSA-N TCA A Natural products CC(CCC(=O)O)C1=CCC2(C)OC3=C(CC12)C(=O)C(O)CC3 GFKPPJZEOXIRFX-UHFFFAOYSA-N 0.000 description 1
- 239000012163 TRI reagent Substances 0.000 description 1
- 102100032497 U3 small nucleolar ribonucleoprotein protein MPP10 Human genes 0.000 description 1
- 101710100179 UMP-CMP kinase Proteins 0.000 description 1
- 101710119674 UMP-CMP kinase 2, mitochondrial Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 108091034131 VA RNA Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 108010079785 calpain inhibitors Proteins 0.000 description 1
- 108010044208 calpastatin Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000003619 fibrillary effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- UKNNCBXEELDDCU-SUJAAXHWSA-N fumagalone Chemical compound O=C[C@@]1(O)CCC(=O)[C@@H](OC)[C@@H]1[C@]1(C)[C@@H](CC=C(C)C)O1 UKNNCBXEELDDCU-SUJAAXHWSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- NESRXFGQJARQNM-OWYFMNJBSA-N graphinone Chemical compound O=C([C@H]([C@]1(O)[C@]2(C)[C@H](O2)CC=C(C)C)OC)CC[C@@]21CO2 NESRXFGQJARQNM-OWYFMNJBSA-N 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 108091022911 insulin-like growth factor binding Proteins 0.000 description 1
- 102000028416 insulin-like growth factor binding Human genes 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000025278 malignant myoepithelioma Diseases 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 238000011880 melting curve analysis Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 101150026150 mt gene Proteins 0.000 description 1
- 201000008405 myoepithelial carcinoma Diseases 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 201000008016 ovarian benign neoplasm Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010055499 ponsin Proteins 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 108091029842 small nuclear ribonucleic acid Proteins 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004572 zinc-binding Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53350503P | 2003-12-31 | 2003-12-31 | |
| US533505P | 2003-12-31 | ||
| PCT/US2004/043837 WO2005066371A2 (en) | 2003-12-31 | 2004-12-30 | Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2394799T3 true ES2394799T3 (es) | 2013-02-05 |
Family
ID=34748910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04815833T Expired - Lifetime ES2394799T3 (es) | 2003-12-31 | 2004-12-30 | Métodos para predecir y superar la resistencia a quimioterapia en cáncer de ovario |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US7700280B2 (enExample) |
| EP (2) | EP1704250B1 (enExample) |
| JP (3) | JP4682152B2 (enExample) |
| CN (3) | CN102321584B (enExample) |
| ES (1) | ES2394799T3 (enExample) |
| TW (1) | TWI301066B (enExample) |
| WO (1) | WO2005066371A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4682152B2 (ja) * | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
| AU2006249235B2 (en) * | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| US8420603B2 (en) * | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| ES2529660T3 (es) * | 2004-05-14 | 2015-02-24 | Abraxis Bioscience, Llc | Métodos de tratamiento en los que se utilizan las proteínas de unión a albúmina como dianas |
| US7553496B2 (en) * | 2004-12-21 | 2009-06-30 | University Of Kentucky Research Foundation | VEGF-A as an inhibitor of angiogenesis and methods of using same |
| US8445198B2 (en) | 2005-12-01 | 2013-05-21 | Medical Prognosis Institute | Methods, kits and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| EP1960551A2 (en) * | 2005-12-01 | 2008-08-27 | Medical Prognosis Institute | Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy |
| MX2008015969A (es) * | 2006-06-13 | 2009-03-26 | Univ Rockefeller | Productos terapeuticos y de diagnostico y metodos novedosos. |
| DE102006035393A1 (de) * | 2006-11-02 | 2008-05-15 | Signature Diagnostics Ag | Prognostische Marker für die Klassifizierung des dreijährigen progessionsfreien Überlebens von Patienten mit Kolonkarzinomen basierend auf Expressionsprofilen von biologischen Proben |
| US20110178154A1 (en) * | 2007-02-06 | 2011-07-21 | Birrer Michael J | gene expression profile that predicts ovarian cancer subject response to chemotherapy |
| WO2008109519A2 (en) * | 2007-03-02 | 2008-09-12 | University Of South Florida | Micro-rna profiles associated with endometrial cancer development and response to cisplatin and doxorubicin chemotherapy |
| EP3399520B1 (en) | 2007-09-11 | 2022-01-05 | University of Massachusetts | Insulin-like growth factor binding protein 7 for use in treatment of cancer |
| CA2713296A1 (en) * | 2008-01-31 | 2009-08-06 | Keio University | Method for determination of sensitivity to anti-cancer agent |
| US8093000B2 (en) * | 2008-05-09 | 2012-01-10 | The Regents Of The University Of California | Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation |
| WO2010135786A1 (en) * | 2009-05-29 | 2010-12-02 | Clinical Genomics Pty. Ltd. | A method for diagnosing neoplasms and molecules for use therein |
| CN102625839A (zh) * | 2009-07-09 | 2012-08-01 | 阿布拉西斯生物科学有限责任公司 | Sparc反义组合物和其用途 |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| AU2010295324B2 (en) * | 2009-09-18 | 2015-04-30 | Abraxis Bioscience, Llc | Use of the SPARC microenvironment signature in the treatment of cancer |
| CN105699638B (zh) * | 2009-10-30 | 2018-05-22 | 学校法人庆应义塾 | 抗癌剂感受性的判定方法 |
| CA2800557A1 (en) | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
| WO2011150022A2 (en) | 2010-05-25 | 2011-12-01 | Syndevrx, Inc. | Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof |
| CA2801190A1 (en) | 2010-06-03 | 2011-12-08 | Abraxis Bioscience, Llc | Use of the sparc microenvironment signature in the treatment of cancer |
| WO2012110425A1 (en) * | 2011-02-14 | 2012-08-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for monitoring the response to treatment and for treating colorectal cancer |
| KR20140044341A (ko) * | 2011-06-02 | 2014-04-14 | 알막 다이아그노스틱스 리미티드 | 암에 대한 분자적 진단 검사 |
| WO2013036850A2 (en) * | 2011-09-09 | 2013-03-14 | University Of Massachusetts | Modulation of midbody derivatives |
| WO2014087156A1 (en) | 2012-12-03 | 2014-06-12 | Almac Diagnostics Limited | Molecular diagnostic test for cancer |
| ES2749746T3 (es) | 2013-04-10 | 2020-03-23 | Syndevrx Inc | Inhibidores de fumagilol metap2 modificados o conjugados con polímeros para uso en el tratamiento de la obesidad |
| GB201409479D0 (en) | 2014-05-28 | 2014-07-09 | Almac Diagnostics Ltd | Molecular diagnostic test for cancer |
| CN103893763B (zh) * | 2014-04-10 | 2016-05-11 | 武汉大学 | Vinexin-β基因在心肌梗死中的应用 |
| SI3173382T1 (sl) * | 2014-07-21 | 2023-04-28 | Oxolife, S. L. | Volframove (VI) soli za stimuliranje plodnosti in reprodukcije ter za izboljšanje učinkovitosti tehnik asistirane reprodukcije |
| DK3198035T3 (da) | 2014-09-26 | 2023-01-30 | Allarity Therapeutics Europe ApS | Fremgangsmåder til forudsigelse af medicinrespons |
| US9969722B2 (en) | 2015-12-10 | 2018-05-15 | Syndevrx, Inc. | Fumagillol derivatives and polymorphs thereof |
| CN114225045B (zh) * | 2016-01-11 | 2025-09-26 | 辛德弗雷克斯公司 | 代谢功能障碍引起的肿瘤的治疗 |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| CA3083242A1 (en) * | 2017-11-21 | 2019-05-31 | Naofumi MIWA | Human cancer cell metastasis inhibitory agent and human cancer cell determination agent |
| CA3115315A1 (en) | 2018-10-15 | 2020-04-23 | Anthony A. HYMAN | Compounds for treatment of diseases and methods of screening therefor |
| AU2019366819C1 (en) | 2018-10-26 | 2025-12-18 | Syndevrx Inc. | Biomarkers of MetAP2 inhibitors and applications thereof |
| SG11202106690QA (en) | 2019-02-08 | 2021-07-29 | Dewpoint Therapeutics Inc | Methods of characterizing condensate-associated characteristics of compounds and uses thereof |
| EP3969122A4 (en) * | 2019-05-15 | 2024-01-17 | Whitehead Institute For Biomedical Research | METHODS OF CHARACTERIZATION AND METHODS OF USING AGENT-CONDENSATE INTERACTIONS |
| CN110331203B (zh) * | 2019-07-30 | 2023-04-18 | 中南大学湘雅三医院 | 泛素连接酶chaf1b作为靶位点在制备肺腺癌顺铂增敏药物中的应用 |
| WO2021055644A1 (en) | 2019-09-18 | 2021-03-25 | Dewpoint Therapeutics, Inc. | Methods of screening for condensate-associated specificity and uses thereof |
| KR20240000560A (ko) * | 2021-04-26 | 2024-01-02 | 크리티테크, 인크. | 시스플라틴 입자 및 이의 용도 |
| US20250304625A1 (en) * | 2022-04-06 | 2025-10-02 | Vanderbilt University | Articles and methods for inhibiting methionine aminopeptidase activity |
| WO2025057928A1 (ja) * | 2023-09-11 | 2025-03-20 | 国立大学法人大阪大学 | 細胞外小胞内ｒｎａ修飾による卵巣癌プラチナ製剤抵抗性を判別するための検査方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993023569A1 (en) | 1992-05-11 | 1993-11-25 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for inhibiting viral replication |
| JPH07509133A (ja) | 1992-07-17 | 1995-10-12 | リボザイム・ファーマシューティカルズ・インコーポレイテッド | 動物疾患の処置のための方法および剤 |
| US5624803A (en) | 1993-10-14 | 1997-04-29 | The Regents Of The University Of California | In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom |
| US5902880A (en) | 1994-08-19 | 1999-05-11 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
| US7625697B2 (en) * | 1994-06-17 | 2009-12-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for constructing subarrays and subarrays made thereby |
| US6146886A (en) | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
| WO1996018736A2 (en) | 1994-12-13 | 1996-06-20 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of arthritic conditions, induction of graft tolerance and reversal of immune responses |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| JP2001510808A (ja) | 1997-07-24 | 2001-08-07 | イネックス ファーマシューティカルズ コーポレイション | 核酸触媒の供給のためのリポソーム組成物 |
| AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
| JP2003528024A (ja) | 1997-12-16 | 2003-09-24 | バレンティス・インコーポレーテッド | 製剤化された核酸分子の無針注入 |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6680175B2 (en) * | 1998-05-05 | 2004-01-20 | Adherex Technologies, Inc. | Methods for diagnosing and evaluating cancer |
| GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
| CA2361201A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| WO2000053722A2 (en) | 1999-03-10 | 2000-09-14 | Phogen Limited | Delivery of nucleic acids and proteins to cells |
| WO2001012781A1 (en) * | 1999-08-13 | 2001-02-22 | Human Genome Sciences, Inc. | 13 human colon and colon cancer associated proteins |
| JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのｒｎａ干渉経路遺伝子 |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| AU2001238493A1 (en) * | 2000-02-17 | 2001-08-27 | Millennium Pharmaceuticals, Inc | Methods and compositions for the identification, assessment, prevention and therapy of human cancers |
| AU2001253140A1 (en) * | 2000-04-03 | 2001-10-15 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Tumor markers in ovarian cancer |
| EP1356097A2 (en) | 2000-08-11 | 2003-10-29 | City of Hope | The anti-neoplastic agent et-743 inhibits trans activation by sxr |
| US20040096915A1 (en) * | 2000-10-27 | 2004-05-20 | Diamandis Eleftherios P. | Methods for detecting ovarian cancer |
| WO2002046765A2 (en) * | 2000-11-08 | 2002-06-13 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer |
| US7195868B2 (en) * | 2001-04-18 | 2007-03-27 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the identification, assessment, prevention, and therapy of human cancers |
| WO2003039327A2 (en) | 2001-11-02 | 2003-05-15 | Dana-Farber Cancer Institute | Methods and compositions for the diagnosis of cancer susceptibilities and defective dna repair mechanisms and treatment thereof |
| AU2002357017A1 (en) * | 2001-11-28 | 2003-06-10 | Mediomics, Llc | Anti-angiogenesis methods, compositions and uses therefor |
| WO2003078603A2 (en) * | 2002-03-15 | 2003-09-25 | Board Of Regents, The University Of Texas System | Strong gene sets for glioma classification |
| US20040097452A1 (en) * | 2002-11-19 | 2004-05-20 | Isis Pharmaceuticals Inc. | Modulation of kallikrein 6 expression |
| JP4682152B2 (ja) * | 2003-12-31 | 2011-05-11 | ザ・ペン・ステート・リサーチ・ファンデーション | 卵巣がんの化学療法に対する抵抗性を予測および克服するための方法ならびに結腸がんの発生を予測するための方法 |
| WO2006044017A2 (en) * | 2004-08-13 | 2006-04-27 | Jaguar Bioscience Inc. | Systems and methods for identifying diagnostic indicators |
-
2004
- 2004-12-30 JP JP2006547537A patent/JP4682152B2/ja not_active Expired - Fee Related
- 2004-12-30 WO PCT/US2004/043837 patent/WO2005066371A2/en not_active Ceased
- 2004-12-30 EP EP04815833A patent/EP1704250B1/en not_active Expired - Lifetime
- 2004-12-30 CN CN201110195193.7A patent/CN102321584B/zh not_active Expired - Fee Related
- 2004-12-30 CN CN2004800421486A patent/CN1922332B/zh not_active Expired - Fee Related
- 2004-12-30 CN CN201210472073.1A patent/CN102989009B/zh not_active Expired - Fee Related
- 2004-12-30 ES ES04815833T patent/ES2394799T3/es not_active Expired - Lifetime
- 2004-12-30 EP EP11163049.7A patent/EP2395112B1/en not_active Expired - Lifetime
- 2004-12-30 US US11/026,734 patent/US7700280B2/en not_active Expired - Lifetime
- 2004-12-31 TW TW093141829A patent/TWI301066B/zh not_active IP Right Cessation
-
2010
- 2010-02-23 US US12/711,068 patent/US8192935B2/en not_active Expired - Fee Related
- 2010-02-23 US US12/711,056 patent/US20100221730A1/en not_active Abandoned
- 2010-02-23 US US12/711,036 patent/US20100221729A1/en not_active Abandoned
- 2010-03-31 JP JP2010081265A patent/JP5285012B2/ja not_active Expired - Fee Related
-
2012
- 2012-12-12 JP JP2012271426A patent/JP5789591B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-24 US US15/052,422 patent/US20160348180A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1704250B1 (en) | 2012-09-19 |
| US20100221731A1 (en) | 2010-09-02 |
| JP5285012B2 (ja) | 2013-09-11 |
| TWI301066B (en) | 2008-09-21 |
| CN1922332B (zh) | 2013-06-12 |
| JP2010209076A (ja) | 2010-09-24 |
| WO2005066371A2 (en) | 2005-07-21 |
| US20160348180A1 (en) | 2016-12-01 |
| CN102321584B (zh) | 2014-01-08 |
| CN102989009B (zh) | 2015-06-03 |
| EP2395112B1 (en) | 2017-02-15 |
| EP2395112A1 (en) | 2011-12-14 |
| WO2005066371A3 (en) | 2006-04-20 |
| CN102989009A (zh) | 2013-03-27 |
| EP1704250A2 (en) | 2006-09-27 |
| TW200531682A (en) | 2005-10-01 |
| US8192935B2 (en) | 2012-06-05 |
| CN102321584A (zh) | 2012-01-18 |
| US20100221729A1 (en) | 2010-09-02 |
| CN1922332A (zh) | 2007-02-28 |
| JP2013079261A (ja) | 2013-05-02 |
| US7700280B2 (en) | 2010-04-20 |
| JP4682152B2 (ja) | 2011-05-11 |
| JP5789591B2 (ja) | 2015-10-07 |
| JP2007517058A (ja) | 2007-06-28 |
| US20100221730A1 (en) | 2010-09-02 |
| US20050176669A1 (en) | 2005-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2394799T3 (es) | Métodos para predecir y superar la resistencia a quimioterapia en cáncer de ovario | |
| Li | Survivin study: what is the next wave? | |
| JP5770472B2 (ja) | ヒト急性白血病におけるｅｐｈａ７及びｅｒｋリン酸化の調節解除を誘発するための方法及び組成物 | |
| JP5764822B2 (ja) | がんの治療および診断の標的遺伝子としてのｐｒｍｔ１ | |
| JP2012500389A (ja) | 多発性脊髄腫の診断、予後および治療のためのマイクロｒｎａに基づく組成物および方法 | |
| Cai et al. | USP18 deubiquitinates and stabilizes Twist1 to promote epithelial-mesenchymal transition in glioblastoma cells | |
| Zhao et al. | LncRNA TMPO‐AS1 promotes LCN2 transcriptional activity and exerts oncogenic functions in ovarian cancer | |
| EP3156497A1 (en) | Trpv2 as a biomarker and as a therapeutic target for melanoma | |
| CA2487427A1 (en) | Methods and compositions for treating neoplasia relating to hnrnp a1 and a2 nucleic acid molecules | |
| EP2436694B1 (en) | Novel gpcr protein and use of same | |
| JP2009502113A (ja) | 乳癌を治療するための組成物および方法 | |
| KR101808658B1 (ko) | 암 진단 키트 및 암 예방 또는 치료용 약제학적 조성물 | |
| WO2008069621A1 (en) | Novel use of mig12 and oip5 genes | |
| KR101115446B1 (ko) | 대장암 진단용 조성물 및 그 용도 | |
| KR101115443B1 (ko) | 대장암 진단용 조성물 및 그 용도 | |
| WO2024062445A1 (en) | Treatment and method for predicting disease incidence, progression, and prognosis of glioma | |
| WO2025095040A1 (ja) | 抗腫瘍剤、抗腫瘍剤のスクリーニング方法、および予後検査薬 |